Literature DB >> 11079550

Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2.

M W Becher1, J A Kotzuk, L E Davis, D G Bear.   

Abstract

Intranuclear inclusions are one of the ultrastructural hallmarks of oculopharyngeal muscular dystrophy (OPMD), a disorder caused by small polyalanine (GCG) expansions in the gene that codes for a ubiquitous nuclear protein called poly(A) binding protein 2 (PABP2). We studied OPMD skeletal muscle and found that 1.0 to 10.0% of myocyte nuclei contained discreet PABP2 immunoreactive intranuclear inclusions, providing the first direct evidence of the relation between the proposed gene for OPMD and the pathology of OPMD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11079550

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

1.  In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1.

Authors:  João Paulo Tavanez; Patricia Calado; José Braga; Miguel Lafarga; Maria Carmo-Fonseca
Journal:  RNA       Date:  2005-04-05       Impact factor: 4.942

2.  Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy.

Authors:  Ami Mankodi; Thurman M Wheeler; Reena Shetty; Kelly M Salceies; Mark W Becher; Charles A Thornton
Journal:  Neurobiol Dis       Date:  2011-09-21       Impact factor: 5.996

3.  Interactions between homopolymeric amino acids (HPAAs).

Authors:  Yoko Oma; Yoshihiro Kino; Kazuya Toriumi; Noboru Sasagawa; Shoichi Ishiura
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

Review 4.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

5.  Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome.

Authors:  Amy Krans; Michael G Kearse; Peter K Todd
Journal:  Ann Neurol       Date:  2016-11-26       Impact factor: 11.274

6.  PABPN1 gene therapy for oculopharyngeal muscular dystrophy.

Authors:  A Malerba; P Klein; H Bachtarzi; S A Jarmin; G Cordova; A Ferry; V Strings; M Polay Espinoza; K Mamchaoui; S C Blumen; J Lacau St Guily; V Mouly; M Graham; G Butler-Browne; D A Suhy; C Trollet; G Dickson
Journal:  Nat Commun       Date:  2017-03-31       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.